Puma Biotechnology Q2 Adj EPS $0.10 Beats $0.07 Estimate, Sales $54.60M Beat $51.37M Estimate
Portfolio Pulse from mahesh@benzinga.com
Puma Biotechnology (NASDAQ:PBYI) reported Q2 earnings of $0.10 per share, beating the analyst consensus estimate of $0.07 by 42.86%. However, this is a 64.29% decrease from the same period last year. The company also reported quarterly sales of $54.60 million, beating the estimate of $51.37 million by 6.29%, but this is an 8.24% decrease from last year.
August 04, 2023 | 2:24 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Puma Biotechnology's Q2 earnings and sales beat estimates but are down from last year.
While Puma Biotechnology beat estimates for Q2 earnings and sales, the decrease from the same period last year could potentially concern investors. This mixed result makes the short term impact on the stock price uncertain.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100